Investment
Features
FeesSafety
Academy
More
Pluang+

Veraxa Biotech shows promising in vivo data for safer, effective BiTAC-ADC cancer therapy.

Market News
13 Oct 2026
GlobeNewsWire
View Source
Bullish
Veraxa Biotech shows promising in vivo data for safer, effective BiTAC-ADC cancer therapy.

Veraxa Biotech presented in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress, demonstrating potent tumor reduction in a breast cancer model with a single systemic dose. The BiTAC-ADC platform selectively activates a prodrug payload inside tumor cells, showing strong anti-tumor effects and a differentiated safety profile compared to conventional ADCs, with no significant body weight loss observed. This dual-targeting approach aims to improve precision and reduce systemic toxicity, marking a significant step toward safer cancer treatments. The company plans to advance this technology further in its R&D and partnering strategies.

Veraxa Biotech's recent presentation on BiTAC-ADC technology comes amid a health sector where 80 of 128 US stocks traded on Pluang rose today. For readers following health stocks, as of Oct 13, 2026 16:51 WIB, notable movers include TLRY at USD 3.30 with a 1-day change of -1.79% and a Pluang order activity of 1% Sell / 99% Buy, INCY at USD 109.38 down 1.78% with 0% Sell / 100% Buy, and LFST at USD 12.69 up 1.68% with a typical hold time of 4 days.

More News

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger stock dips 5% amid $55M Tectora co-founding and upcoming earnings forecast.

Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...

Analyst Insights
Bullish
49 minutes ago
Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson beats Q3 earnings estimates, driven by strong pharmaceutical growth.

Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...

Company Fundamentals
Bullish
57 minutes ago
TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC Q3 revenue beats forecasts as AI chip demand fuels strong growth.

TSMC's preliminary Q3 2026 revenue reached approximately NT$1.49 trillion, about 50% higher year-over-year and above management guidance, driven by strong AI chip demand. The company holds a dominant 73% share of the global pure-play foundry market, ...

Company Fundamentals
Bullish
1 hour ago
Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey launch Growth Signals to capture insights from fast-growing businesses.

Inc. and SurveyMonkey have launched Growth Signals, a new initiative to regularly poll entrepreneurs and business leaders of fast-growing companies. This program aims to capture their priorities, challenges, and growth outlook to inform Inc.'s editor...

Others
Neutral
1 hour ago
BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard launches new website with real-time treasury dashboard to boost transparency and educate investors.

BNB Standard Corporation has launched a new corporate website featuring an expanded treasury dashboard that updates its Adjusted Net Asset Value and other key financial metrics intraday. This move aims to increase transparency and accountability in t...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App